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Abstract Primary immunodeficiencies (PIDs) are a widely
heterogeneous group of inherited defects of the immune sys-
tem consisting of many clinical phenotypes with at least 300
underlying genetic deficits currently known. Patients with
PIDs can present with, or develop during the course of their
life, a susceptibility to recurrent and chronic infection along
with autoimmune, allergic, inflammatory, and/or proliferative
disorders, all potentially leading to end-organ damage. In re-
cent years, a combination of basic and clinical research has
greatly improved understanding of the underlying immuno-
logical and genetic defects in PIDs, leading to improved
diagnosis, classification, and treatment approaches. In this re-
view, we consider some of the key understandings that should
direct diagnostic and treatment approaches in PID and offer
insights into current and emerging management approaches
and the lifelong care of patients from childhood through to
adulthood.
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Introduction
The term Bprimary immunodeficiency (PID) diseases^
describes a heterogeneous group of disorders which
have in common poor or absent function in components
of the innate and/or adaptive immune systems. New
PIDs continue to be characterized as scientific and clin-
ical understanding of these rare conditions advances [1,
2]. Recent decades have seen marked improvements in
both the diagnosis and management of PIDs that have
altered the outlook for many patients but which at the
same time bring new challenges and add new complex-
ities to the care of patients with PIDs. Since the early
1990s, molecular understanding of PIDs has increased
greatly and there are now over 300 recognized and de-
fined PIDs [1, 3]. In terms of the numbers of patients
a f f e c t ed by P IDs , t he Eu ropean Soc i e t y fo r
Immunodeficiencies (ESID) Registry captures patient
data from over 125 centers across Europe, and in
2014 recorded information on more than 20,000 PID
patients [4]. The existence of such registries and collab-
oration between centers managing patients with PID
he lps to suppor t be t t e r unde rs t and ing of the
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epidemiological analyses of PID genotypes and pheno-
types and is also crucial for the study and development
of improved diagnostic and treatment interventions.
Although general awareness about PIDs remains
patchy, there is much active and ongoing research. In
this article, based on the proceedings of a symposium
he l d du r i ng t h e 2015 In t e r n a t i on a l P r ima ry
Immunodeficiencies Congress (IPIC 2015), we consider
contemporary approaches to the diagnosis of PIDs and
how improvements in the knowledge of pathophysiology
and in our ability to both diagnose and characterize
PIDs have changed patient management in recent de-
cades, leading to greater survival in children who used
to have a shortened life expectancy. The natural history
of disease course has been greatly modified by improve-
ments in management and care. We consider the current
and future therapeutic approaches and treatment oppor-
tunities that may bring further advances in patient care,
and we reflect on how to support and manage the grow-
ing number of PID patients, particularly in their transi-
tion from pediatric to adult healthcare services.
Diagnosis of PIDs—a Continually Evolving Story
Early diagnosis of PIDs remains a key goal; and in
considering the available literature and evidence, it is
important to draw a distinction between diagnostic tech-
niques and innovations that have allowed for the dis-
covery and description of Bnew^ disorders, versus the
diagnostic investigations that can be employed today
in everyday clinical practice. Access to genetic tests in
routine practice varies between specialist centers and
countries. Today, the wait for results from many genetic
tests can take months. Moving forward, what is needed
are easily accessible, affordable, and rapid tests for all
known PIDs.
Diagnostic discoveries and advances have consider-
ably changed and improved the management of patients
with PID in recent years [5]. Patients who 15–20 years
ago would have defied categorization, or been without a
clear diagnosis, might today benefit from novel diagnos-
tic modalities, hope for a more definitive diagnosis, and
therefore more appropriate management. Examples from
our own case files (Box 1) as well as from the medical
literature attest to how PID diagnosis has evolved and
continues to evolve. In the case example of the first
young female patient given in Box 1, until the papers
of Lilic et al. at the turn of the millennium and the
seminal publication by van de Veerdonk et al. in 2011
[6–9], it was not understood that gain-of-function
STAT1 mutations impairing IL-17 immunity lay behind
the deregulation of cytokines and the defective Th1 and
Th17 responses seen in the PID of chronic mucocutane-
ous candidiasis.
Box 1. Historical case examples: Case examples that took ~20 years
before a definitive diagnosis was reached (Andrew Cant personal case
file examples)
Girl—born 1987
• 3 months of age: candida (oral and napkin)
• Oesophageal strictures
1988/9
• 1 year: repeated LRTI; diarrhoea; FTT; bronchiectasis; CD4
lymphopenia No Igs; CMV in urine
• Chronic mucocutaneous candidiasis
Persistent and debilitating
Selective (C. albicans)
No systemic candidiasis
Autoimmunity (AIRE): multi-organ specific (polyendocrinopathy—
APS-1) excluded
• Immunodeficiency: ? cause—selective to candida?
2011
• Diagnosis in 2011: STAT1 mutation
LRTI lower respiratory tract infection, FTT failure to thrive, CMV
cytomegalovirus, Igs immunoglobulin, AIRE autoimmune regulator
Girl—born 1995
2001
• Ear and chest infections for 2–3 years
• CT scan—bronchial wall thickening
• PFTs normal
• Mother reported having ear & chest infections as child (IgG 4.5)
2007
• No naïve T or CSM B cells
• Cx glands settled
• AR hyper IgM excluded
BCVID^ but IVIG Rx declined by parents
2014
• PI3KCD sequencing normal
• PI3KR1 G > A splice site mutation
• BAPDS2^ (mother same defect)
PFT pulmonary function test, CSM class-switched memory, Cx chest
X-ray, AR autosomal recessive, IgM/G immunoglobulin M/G, IVIG
intravenous immunoglobulin, PI3KCD & PI3KR1 genes encoding the
catalytic subunit of phosphatidylinositol 3-kinase δ (PI3K δ) and
phosphoinositide-3-kinase, regulatory subunit 1, respectively, APDS2
activated PI3K delta syndrome 2
Today, advances in our ability to diagnose certain PIDs
much earlier in childhood have the potential to radically alter
patient outcomes and survival [5] . One such example is the
development of diagnostic modalities such as T cell receptors
excision circle assays with the potential to detect severe com-
bined immune deficiency (SCID) at birth from Guthrie dried
blood spot samples—an advance that could allow for earlier
and potentially curative intervention in a condition that, if
undiagnosed, is associated with almost 100%mortality within
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the first 2 years of life. It has been clearly demonstrated that
early diagnosis is associated with better outcomes in infants
affected by SCID [10, 11]. There are therefore increasing calls
for SCID diagnosis to become part of mandatory newborn
disease screening [12].
Another example of change and continuing evolution in
PID is our improved understanding and approach to the diag-
nosis of common variable immunodeficiency disorders
(CVIDs) [13–15]. The term CVID describes a heterogeneous
set of disorders that are collectively characterized by defective
antibody production and which can have a highly variable
clinical presentation typified by recurrent infection of the re-
spiratory tract [16–18]. Readers are referred to recent publica-
tions for fuller details of the diagnostic criteria that apply in
CVID [13–15], ESID Working Clinical Criteria (available
here: www.esid.org/working-parties/Registry), and to recent
publ i ca t ions descr ib ing cur ren t PID and CVID
classifications [1].
While survival of patients with CVIDs has improved in
recent decades due in part to the wider availability and ad-
vances in immunoglobulin replacement therapy, this has ex-
posed a risk of morbidity and mortality in CVID due to sec-
ondary, non-infectious complications of disease that may in-
clude autoimmunity and inflammatory diseases, functional
and structural lung disease, liver diseases, and the develop-
ment of malignancies [15, 16]. We now appreciate that these
secondary complications need to be actively searched out, as
part of any diagnosis and patient phenotyping, as well as
throughout continuing patient assessment [18, 19].
Diagnosis on the basis of clinical presentation and close
clinical scrutiny of the patient and their history remain of
paramount and primary importance; but today, they are not
sufficient alone to reach an accurate diagnosis of a CVID
because of the large degree of overlap in phenotypes and the
variable presentation of different genetic disorders, whichmay
present like CVID but which do not constitute a CVID diag-
nosis [13, 14] (Fig. 1).
Among patients diagnosed with CVID, the number with
undiagnosed combined immunodeficiency is generally
underestimated, and this is a group that needs urgently to be
identified through better clinical, laboratory, and increasingly
genetic assessment.
The infection profile in CVIDs has been examined in
several reports, such as those from the French DEF-I
national study in which it was found that upper respi-
ratory tract infections (URTIs) are highly prevalent and
often manifest early as presenting features in CVID
[20]. Unusual, opportunistic infections need to be
interpreted as potential signs of a combined immunode-
ficiency [21], and patients presenting with these need to
be further evaluated even when formally fulfilling the
criteria for CVID. Similarly, clinical signs of immune
dysregulation—often termed as complex CVID pa-
tients—should alert for a diagnostic work-up for com-
bined immunodeficiency and end-organ disease(s).
As many as 30% of patients with CVID have autoimmune
manifestations [16]. Based on next-generation sequencing, in-
creasingly, combined immunodeficiencies are being discovered
among CVID-like patients [22] . It is important to recognize
and dissect out signs of immune dysregulation and autoimmu-
nity—including inflammatory disorders—and be alert to the
possibility of symptoms suggestive of underlying comorbidi-
ties (such as autoimmunity, lymphoproliferative disorders, or
organ damage including cytopenia, granulomatous diseases,
lymphoma, interstitial lung disease, bronchiectasis, spleno-
megaly, or autoimmune enteropathy) that all warrant further
investigation for combined immunodeficiency by in-depth T
cell analysis (See BImmune dysregulation—Pathogenic
Concepts^).
Indeed, we recommend that any patient with a suspected
diagnosis of so-called complex CVID should be referred to
PID-specialist centers. Assessments of immune function should
aim to delve beyond the primary hypogammaglobulinaemia that
characterizes CVID [13], to include close analyses of serum
Immune functionClinic presentation
Signs of combined ID
End organ disease
T cell parameters
Signalling studies
Confirming new variants
Genetics
New born screening
Next generation sequencing
ALWAYS IMPORTANT!
Fig. 1 The three key diagnostic
aspects of immunodeficiency to
consider in CVID
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IgG, IgA, and IgM levels and the assessment of specific anti-
body responses, together with thorough evaluation of the pa-
tient’s small lymphocyte panel and B (especially of switched
memory B cells and CD21low B cells) and T cell parameters
(especially of naïve CD4 T cells) using methods and cut-offs
that exclude other diagnoses, as far as it is possible, and better
define the immune profile of the patient with a CVID [15] (See
ESID Working Clinical Criteria [23] and See below BImmune
dysregulation—Pathogenic Concepts^).
While a genetic work-up is not recommended as a routine
in the initial evaluation of all suspected CVID, exceptions
should be made, such as in patients with a known consanguin-
eous background or positive family history and in instances
where laboratory studies strongly suggest an underlying ge-
netic disease (See subsection below on emerging role for ge-
netics). Genetic investigations are necessary in all patients
with a complex CVID presentation and history in order to
examine early on for monogenic defects presenting with im-
mune dysregulation.
Next-generation sequencing (NGS) has almost superseded
conventional Sanger DNA sequencing, and although not widely
available in routine clinical practice, looks set to revolutionize
genomic research and is already helping to identify new genetic
syndromes with immune dysregulation and deficiency [5,
24–31] . NGS has revealed that the phenotype of single gene
defects can vary more than expected and that many genetic
defects have overlapping phenotypes. Genetic analyses using
NGS have shown, for example, that mutations in lipopolysac-
charide responsive beige-like anchor protein (LRBA) lead to an
immune deficiency characterized by T and B cell defects, au-
tophagy and apoptosis, and a clinical phenotype of childhood
onset hypogammaglobulinaemia and autoimmunity [24]. NGS
has identified loss of function mutations in protein kinase C
delta as underlying a B cell hyperproliferation syndrome [25]
and gain-of-function mutations in the PI3K-phosphoinositide 3-
kinase (PIK3CD) gene in activated PI3kinase delta syndrome
(APDS) patients [26, 27].
Immune Dysregulation—Pathogenic Concepts
Better understanding of the key pathomechanisms of
immune dysregulation at play in CVIDs may hold the
key to improved diagnosis and treatment of CVIDs and
other PIDs in the future [22, 32].
Our concepts of the activation of the immune system are
founded on the core principles that the immune system is
designed around self/non-self-recognition, assessment of dan-
ger and integration of the signals between and inside partici-
pating cells [33, 34]. In conditions of immune dysregulation, it
therefore follows that we might expect to find disturbed selec-
tion or production of immune cells, altered activation of im-
mune cells and mediators, impaired regulatory T cell (Treg)
homeostasis or function, and increased danger signalling [22].
In recent years, several defects in signallingmolecules have
demonstrated the association of disturbed antigen receptor
signalling and autoimmune manifestations. Thus, patients
with deficiency in the inducible T cell kinase (ITK) deficiency
[35] or in the stromal interaction molecule 1 (STIM1) often
present with clinical signs of disturbed immune tolerance.
Protein kinase C delta (PKC-delta) deficiency is linked with
defective B cell apoptosis and hyperproliferation and mani-
fests as a systemic lupus erythematosus (SLE) phenotype [25,
36, 37]. In the APDS gain-of-function mutations of the
phosphatidylinositol-3-OH kinase (PI3K), p110-delta or its
regulatory component p85-alpha affects immune responses
and stimulates abnormal cell proliferation, lymphadenopa-
thies, and B cell lymphoma [26, 27].
The underlying cause and the clinical impact of reduced
regulatory T cells seen in many CVID patients with autoim-
munity are not understood but may contribute to the complex-
ity of the immune dysregulation [38]. However, CTLA-4 de-
ficiency has underlined how altered Treg function and im-
mune regulation can lead to secondary immunodeficiency in
several patients previously diagnosed as BCVID^ [27, 28].
There has also been evidence for links between inflamma-
tion and the up-regulation of interferon (IFN)-responsive
genes in patients with complex CVID [39]. An altered cross-
talk between gut microbiota, the intestinal epithelium, and the
immune system may lead to bacterial translocation, Toll-like
receptor (TLR)-activation, and IFN-induction, and this ap-
pears to contribute to the CD4 Tcell exhaustion and functional
impairment observed in some CVID patients [40, 41]. Our
current understanding of these mechanisms contributing to
the pathogenesis of immune dysregulation is still very rudi-
mentary (Fig. 2).
Current and Future Perspectives on PID Management
Management decisions for patients with PIDs need to be
based more and more on all three aspects of diagnosis—the
clinical presentation, an understanding of the patient’s im-
mune function test results, and the underlying genetic defect.
Currently, in most cases, management decisions will be led by
the clinical presentation.
This may involve the use of anti-infectious prophylaxis and
the aggressive treatment of infections; however, for most pa-
tients with antibody deficiency, the cornerstone of therapy is
immunoglobulin replacement therapy, the goal of which is to
prevent most infections [18, 42–44]. Many studies show that
immunoglobulin replacement therapy significantly reduces
the rate of acute and chronic infection and greatly improves
survival. Seminal studies that have helped guide and direct the
optimal use of immunoglobulin replacement therapy in the
management of CVID for example include the 22-year patient
follow-up study of Lucas et al. and studies assessing the im-
pact of immunoglobulin replacement therapy on pneumonia
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incidence in PIDs [44, 45]. These studies underscore the im-
portance of maintaining adequate trough plasma levels of IgG
in order to control infection and significantly reduce the se-
quelae of acute and/or recurrent infections in PIDs. However,
this treatment fails to control most secondary autoimmune and
inflammatory complications.
Therefore, an improved understanding of the immunopath-
ological and genetic defects in PIDs is key and will help to
shed light on potential new targets and the possible role of
immune-modifying agents in the future management of
PIDs, autoimmune diseases and other closely linked condi-
tions involving immune dysregulation, malignancy, and in-
flammation. For example, in patients with PIDs where there
are gain-of-function mutations affecting PI3K activity, such as
APDS 1/2, there is emerging data from in vitro studies to
suggest that hyperactivity of mTOR might be amenable to
inhibition bymTOR inhibitors such as rapamycin and that this
agent might impact on T cell defects in a manner that could
theoretically, in turn, affect the clinical course of this PID [27].
Other avenues of research that may yield opportunities for
therapeutic intervention include the study of various STAT
mutations, such as STAT1 mutations associated with impair-
ments in IL-17 immunity, and linked with chronic mucocuta-
neous candidiasis, and STAT3 gain-of-function mutations that
are linked with altered T cell and cytokine signalling and with
lymphoproliferation and autoimmunity with prominent cyto-
penias. Such pathologies suggest that there may be opportu-
nities to study new molecules with pharmacological profiles
such as IL-6 inhibition and JAK inhibition that could impact
on STAT gain-of-function or decrease JAK and STAT3 phos-
phorylation and act to counter the underlying deficits that
define certain PIDs [6–9, 46, 47].
Combined immunodeficiencies are not sufficiently treated
by antibody replacement and some patients may require he-
matopoietic stem cell transplantation (HSCT). The role for
HSCT continues to evolve for this subgroup of PIDs, as sur-
vival with cure of severe PIDs is now possible for up to 90%
of patients undergoing HSCT for severe PIDs [48, 49]. With
newborn screening, SCID is a condition detectable at birth
before secondary complications develop; and with such
screening, early HSCT offers a curative option [12].
Allogeneic HSCT may also offer an option for some patients
with complex CVID, although evidence to date suggests that
this therapeutic approach should be considered in carefully
selected patients ideally at a time when only little or no organ
damage or chronic infection has occurred [50]. It is clear that
advances in donor matching and new hematopoietic stem cell
(HSC) manipulation techniques, such as HLA-haploidentical
HSCT associated with alpha-beta+ T and B cell depletion, are
already changing our approach to HSCT in PIDs [51], and
such advances together with reductions in graft versus host
disease (GVHD) incidence, improved options for reduced in-
tensity conditioning and better anti-infectious treatment op-
tions, will combine to ensure better outcomes following
HSCT in PID patients.
In parallel with improvements in approaches and practices
relating to HSCT, active clinical studies involving gene ther-
apy have been pioneered in the field of PIDs [3]. Lessons from
HSCT have allowed for the study of ex vivo gene transfer in
hematopoietic stem cells as a means of effecting phenotype
correction. First clinical trials performed with gamma retrovi-
ral vectors for adenosine deaminase severe combined immu-
nodeficiency (ADA-SCID), X-linked SCID (SCID-X1), and
Wiskott-Aldrich syndrome (WAS) identified that gene therapy
Immune Dysfunction
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Fig. 2 The overlap and
interconnectivity of states in
which immune dysfunction plays
a part in disease pathology (image
devised by A. Cant)
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is a valid therapeutic option in patients without an HLA-
identical donor. To date, no insertional mutagenesis events
have been reported in ADA-SCID cases managed with gene
therapy, although insertional oncogenesis has been reported in
SCID-X1 and WAS, prompting the development of vector
constructs based on self-inactivating retroviral or lentiviral
vectors [3, 52, 53].
Thus a number of challenges still remain, with many PID
patients still facing protracted times to diagnosis and requiring
lifelong chronic treatment rather than having curative options.
Nevertheless, the long-term outcomes of PID patients have
improved greatly in recent decades, such that many patients
now survive longer and require new support paradigms as
they age and mature.
PID—Increasing Numbers of Patients Transitioning
to Adult Care
Many PIDs emerge in childhood; and with improved thera-
peutic options, life expectancy for patients with PIDs has in-
creased in recent years [13, 42]. This means that many more
PID patients now transition from pediatric to adult healthcare
services, leading to a greater emphasis on the importance of
the transition process. Transition has been defined as BA pur-
poseful, planned process that addresses the medical, psycho-
social, and educational/vocational needs of adolescents and
young adults with chronic physical and medical conditions
as they move from child-centered to adult-oriented health care
systems^ [54].
Transition is an important step for young people with com-
plex health needs or disabilities, and their families, and needs
to be carefully planned and handled [55]. Some countries
already have well-established transition services for patients
with specific lifelong conditions that emerge in childhood,
such as cystic fibrosis, diabetes mellitus, chronic kidney dis-
ease, and epilepsy; but, to date, transition pathways for PID
have been less clearly defined. Of note, the International
Patient Organisation for Primary Immunodeficiencies—
IPOPI has devised a booklet on transition [56].
In the UK, Great Ormond Street Hospital (GOSH) is a
national center involved in the care of pediatric patients with
PIDs. Many of the children cared for at GOSHmove on to the
Royal Free London NHS Foundation Trust (RFH) in London
for ongoing care in adulthood. The two centers have worked
closely to establish best practice guidelines and integrated care
pathways for all adolescents with PID requiring transition to
the RFH (as well as other adult centers in the UK).
The ongoing needs of children with PID depend on their
underlying condition and previous management. Broadly,
they fall into two main groups:
(i) Those who have lifelong conditions that require long-
term medical treatment. Most of these are patients with
various forms of primary antibody deficiency who re-
quire lifelong immunoglobulin replacement therapy, and
many of these are on home immunoglobulin treatment.
(ii) Increasing numbers of patients who have undergone
HSCT or gene therapy for severe PID. All of these indi-
viduals require long-term monitoring. Some are fully
immune reconstituted and lead normal healthy lives, re-
quiring only an annual check-up and monitoring blood
tests. However, significant numbers in this group have
ongoing medical and/or psychological issues, and some
remain on long-term Ig replacement therapy.
Patient to come
 to Adult Hospital?
Transition Algorithm
Transfer patient to
other centre
Refer to Adult Hospital regular 
clinic - use referral template
Refer to Adult Hospital Post 
BMT clinic - use referral template
Book into BMT Paediatric 
Hospital transition clinic. 
Adult Hospital attend.
Book into regular Paediatric 
Hospital transition clinic.
Adult Hospital to attend.
Seen by psychologist and
follow up if appropriate
Attend first Adult 
Hospital clinic with attending 
doctor and nurse
Has patient
had BMT?
Patient
14-16 yrs?
Yes
Yes
YesNo
Decision
Action
Resolved
No
Patient
16-18 yrs?
Offer one off session with 
Adult Hospital psychologist
Consider plan for
transfer to Adult Hospital
Start discussion with 
patient and family
Fig. 3 An example of a transition
algorithm (courtesy of S.
Workman)
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Several issues are particularly important to appreciate
inpatients with a PID diagnosis approaching transition.
Many of these children will have had their diagnosis
since infancy, and they and their families will have
forged close ties with pediatric care providers.
Children and parents often develop very close relation-
ships with the pediatric care team and the prospect of
transferring to an adult environment, and losing the se-
curity of a familiar team can be daunting. Coupled with
this, the stresses of change and maturation during ado-
lescence, with issues of developing autonomy and self-
reliance can impact on behaviors and attitudes. In addi-
tion, many children with a PID diagnosis have complex
multi-system disorders. Some have conditions that have
non-immunological manifestations, and some have com-
plications of PID, and these individuals require multi-
disciplinary/multi-specialty care into adulthood.
Transition planning and transition pathways therefore
need to take into account the multiple aspects of matu-
ration along with the social and personal changes that
will affect the diagnosis, treatment, treatment compli-
ance, and autonomy of the future adult with PID.
Appropriate guidance and support during transition and
regarding different options for treatment and care are
essential to promote and sustain good and acceptable
compliance with long-term management plans.
At GOSH and the RFH, preparation for transition starts early,
and discussions regarding impending change and the need for
transition to adult services often begin with patients and families
from the age of 12 years. The pediatric and adult centers run
joint clinics and follow an agreed handover process (Fig. 3)
designed to ensure that patients and their families enjoy a
smooth transition, with no gaps in care, and have access to
members of both the pediatric team and the adult team during
the period of transition. The period of transition does not have a
time limit: each patient will be assessed on an individual basis.
When the patients have been successfully transferred, members
of the GOSH team continue to have joint clinics at the RFH to
maintain continuity of care. This structured process aims to
ensure that patients and their families are confident of continu-
ing, uninterrupted care and supports sharing of case data and
experiences across the healthcare teams responsible for pediatric
care, adolescent, and adult care.
Conclusions
Primary immune deficiencies are a heterogeneous group of
diseases defined by defects in the immune systems leading
to increased susceptibility to infection, autoimmunity, im-
mune dysregulation, inflammation, end-organ damage, and
malignancy. Great strides have been made in the understand-
ing of the pathogenesis and underlying immunological and
genetic defects that define different PIDs and impact on prog-
nosis and outcomes. Armed with this greater understanding of
PIDs, opportunities for earlier recognition and diagnosis of
otherwise life-threatening conditions have been made possi-
ble; and today, many patients with PIDs can be offered treat-
ments tailored to their condition, which have the potential to
improve outlook and survival. Mainstay treatments such as
IVIG replacement therapy continue to be important for long-
term patient care; and as more is understood about the causes
of PIDs, opportunities for wider use of potentially curative
options, such as HSCT and gene therapy, and for study and
development of disease-targeted therapies improve. Patients
with PIDs continue to need close assessment and care at spe-
cialist centers, where active research and study will pave the
way for improved future and lifelong patient care.
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